2GOLD Executive Committee[DB/OL].Guidelines:Global Strategy for Diagnosis,Management,and Prevention of COPD,November 2006[2006-11-18].http://www.goldcopd.com/Guidelineitem.asp? l1 =2-12 = 1&intId =989.
3Celli BR,MacNee W,Committee members.Standard for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004,23:932-946.
4Celli BR,Cote CG,Marin JM,ct al.The body mass index,airflow obstruction,dyspnea and exercise capacity index in chronic obstructive pulmonary disease.N Engl J Med,2004,350:1005-1012.
5GOLD Executive Committee [ DB/OL ]. Guidelines: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2008. [2008-12-15 ]. http:// www. goldcopd, org/Guidelineitem, asp? 11 = 2&12 = 1&intId = 2003.
6GINA Executive Committee. Global strategy for asthma management and prevention, global initiative for asthma (GINA) 2008 [ 2008 - 12 - 15]. http ://www. ginasthma, org/Guidelineitem. asp?? 11 =2&12 = l&intld =60.
7陈文彬,潘祥林.诊断学.7版.北京:人民卫生出版社,2008:527-545.
8Perng DW, Huang HY, Chen HM, et al. Characteristics of airway inflammation and bronchodilator reversibility in COPD: a potential guide to treatment, 2004,126:375-381.
9Saetta M, Turato G, Baraldo S, et al. Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation. Am J Respir Crit Care Med, 2000, 161(3 Pt 1) : 1016-1021.
10Jones PW, Willits LR, Burge PS, et al. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J, 2003, 21:68-73.
